They need to trial further on more patient using Osprey registry to notify any side effective or effectiveness of the product.
training is required and they have provided that to doctors in Australia who participated in panco trial but as the device is withdrawn from TGA those training won't be of any use... IMO.
the issue that stopping use of the product is not just about lack of training or new product or side effect... IMO and only can tell us what it is.
I hope Hong Kong trial complete recruiting patients in next few months.
i am keeen to know how much they spend on payroll this quarter without doing any sell in EU.
OSL Price at posting:
4.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)